Oncolytics Biotech (TSE:ONC – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Oncolytics Biotech to post earnings of C($0.12) per share for the quarter.
Oncolytics Biotech (TSE:ONC – Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported C($0.05) earnings per share for the quarter, topping the consensus estimate of C($0.15) by C$0.10.
Oncolytics Biotech Stock Performance
Shares of Oncolytics Biotech stock opened at C$1.62 on Wednesday. The company has a quick ratio of 8.86, a current ratio of 9.01 and a debt-to-equity ratio of 1.54. Oncolytics Biotech has a 52 week low of C$1.20 and a 52 week high of C$4.49. The firm’s 50 day moving average is C$1.46 and its two-hundred day moving average is C$1.68. The firm has a market capitalization of C$122.18 million, a P/E ratio of -3.95 and a beta of 1.49.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
- Five stocks we like better than Oncolytics Biotech
- 3 Warren Buffett Stocks to Buy Now
- Garmin Navigates to New Highs Driven By Wearables Trend
- Breakout Stocks: What They Are and How to Identify Them
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What Are Growth Stocks and Investing in Them
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.